Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Blanken, Anna E. | Dutt, Shubir | Li, Yanrong | Nation, Daniel A.; * | for the Alzheimer’s Disease Neuroimaging Initiative
Affiliations: Department of Psychology, University of Southern California, Los Angeles, CA, USA
Correspondence: [*] Correspondence to: Daniel A. Nation, 3620 McClintock Ave, Suite 501, Los Angeles, CA 90089, USA. Tel.: +1 213 740-4503; Fax: +1 213 746 9082; E-mail: danation@usc.edu.
Abstract: Background:Clinical-pathological Alzheimer’s disease (AD) subtypes may help distill heterogeneity in patient presentation. To date, no studies have utilized neuropsychological and biological markers to identify preclinical subtypes with longitudinal stability. Objective:The objective of this study was to empirically derive AD endophenotypes using a combination of cognitive and biological markers. Methods:Hierarchical cluster analysis grouped dementia-free older adults using memory, executive and language abilities, and cerebrospinal fluid amyloid-β and phosphorylated tau. Brain volume differences, neuropsychological trajectory, and progression to dementia were compared, controlling for age, gender, education, and apolipoprotein E4 (ApoE4). Results:Subgroups included asymptomatic-normal (n = 653) with unimpaired cognition and subthreshold biomarkers, typical AD (TAD; n = 191) showing marked memory decline, high ApoE4 rates and abnormal biomarkers, and atypical AD (AAD; n = 132) with widespread cognitive decline, intermediate biomarker levels, older age, less education and more white matter lesions. Cognitive profiles showed longitudinal stability with corresponding patterns of cortical atrophy, despite nearly identical rates of progression to AD dementia. Conclusion:Two clinical-pathological AD subtypes are identified with potential implications for preventative efforts.
Keywords: Alzheimer’s disease, atypical AD, cluster analysis, heterogeneity, neuroimaging
DOI: 10.3233/JAD-190230
Journal: Journal of Alzheimer's Disease, vol. 70, no. 1, pp. 227-239, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl